United Therapeutics CORP

United Therapeutics Corporation announced the appointment of Victor Dzau, M.D., to its Board of Directors, effective July 22, 2026, to enhance its mission in developing transplantable organs and organ alternatives.

United Therapeutics Corporation shareholders approved the 2026 Stock Incentive Plan, replacing the prior plan and authorizing new share grants.

United Therapeutics reported a 2% year-over-year revenue decrease for Q1 2026, totaling $781.5 million, but highlighted positive clinical trial results and strategic development plans.

Nebulized Tyvaso met TETON-1’s primary endpoint in idiopathic pulmonary fibrosis with a 130.1 mL FVC benefit vs placebo and a reduced risk of clinical worsening; an FDA priority-review sNDA is planned by summer 2026.

United Therapeutics announced positive results from its phase 3 ADVANCE OUTCOMES study of ralinepag, showing a 55% reduction in clinical worsening risk for pulmonary arterial hypertension patients.

United Therapeutics Corporation announced record full year 2025 revenues of $3.18 billion, an 11% increase over 2024, driven by strong performance in its Tyvaso product line.

United Therapeutics reports a decrease in net income for Q1 2026 compared to the prior year, driven by increased operating expenses and strategic investments, while advancing key pipeline programs.

United Therapeutics reports robust Q3 2025 revenue growth driven by Tyvaso DPI sales and significant progress in its organ manufacturing and xenotransplantation programs.

United Therapeutics Corporation announced robust second-quarter financial results, fueled by significant growth in Tyvaso DPI sales, while making substantial progress in its innovative organ manufacturing and xenotransplantation programs.

United Therapeutics' Q1 2025 revenue increased by 17% year-over-year, driven by growth in Tyvaso DPI sales and pipeline advancements in IPF and PPF treatments.

United Therapeutics' Q3 2024 results show significant revenue growth, primarily driven by increased sales of Tyvaso DPI and overall expansion in the number of patients using their therapies.

United Therapeutics reports a strong second quarter with revenue growth driven by Tyvaso DPI and advancements in organ manufacturing programs.

United Therapeutics Corporation reported an 11% increase in total revenues for 2025, driven by robust sales of Tyvaso DPI and Orenitram, alongside significant advancements in its organ manufacturing pipeline.

United Therapeutics' 2024 annual report highlights significant revenue growth, particularly driven by Tyvaso DPI, and advancements in manufactured organs and organ alternatives.

United Therapeutics outlines its common stock details, public benefit corporation status, and various corporate governance policies in a recent SEC filing.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 30, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 29, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 28, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 27, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 24, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 23, 2026.

United Therapeutics Corporation has released its 2026 Proxy Statement, detailing proposals for the upcoming Annual Meeting of Shareholders, including director elections, executive compensation, and stock incentive plans.

United Therapeutics Corporation has filed a definitive proxy statement with the SEC.

United Therapeutics Corporation files its definitive proxy statement for the 2025 Annual Meeting of Shareholders, detailing board nominations, executive compensation, and other important corporate governance matters.

United Therapeutics Corporation has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

United Therapeutics' proxy statement highlights strong 2023 financial performance and ambitious goals for future growth, including a $4 billion revenue run rate by mid-decade.

Vanguard Capital Management has reported beneficial ownership of 5.19% of United Therapeutics Corp's common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in United Therapeutics Corp following an internal realignment.

Wellington Management Group LLP and its affiliates have reported a 5.67% beneficial ownership stake in United Therapeutics Corporation common stock.

Wellington Management Group LLP and its affiliates have disclosed a 4.5% beneficial ownership stake in United Therapeutics Corporation, held in the ordinary course of business.

Wellington Management Group LLP and its affiliated entities have reported a 5.5% beneficial ownership stake in United Therapeutics Corporation as of December 31, 2024.

State Street Corporation has filed a Schedule 13G, reporting a 4.9% beneficial ownership stake in United Therapeutics Corp as of December 31, 2024, held for passive investment purposes.